Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests

Hepatology

Volumn 41, Issue 3, 2005, Pages 553-558

  Tripodi, Armando ^a,b   Salerno, Francesco ^a   Chantarangkul, Veena ^a   Clerici, Marigrazia ^a   Cazzaniga, Massimo ^a   Primignani, Massimo ^a   Mannucci, Pier Mannuccio ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROCOAGULANT; PROTEIN C; THROMBIN; THROMBOMODULIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TEST; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMODYNAMICS; HEMOSTASIS; HUMAN; LIVER CIRRHOSIS; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBIN TIME;

ADULT; AGED; BLOOD COAGULATION; FEMALE; HEMORRHAGE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROTEIN C; PROTHROMBIN TIME; THROMBIN;

EID: 14244256300     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20569     Document Type: Article

References (30)

1. Kelly DA, Tuddenham EG. Haemostatic problems in liver disease. Gut 1986;27:339-349.
2. Rapaport SI. Coagulation problems in liver disease. Blood Coagul Fibrinol 2000;11(Suppl 1):S69-S74.
3. Joist JH, George JN. Hemostatic abnormalities in liver and renal disease. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:955-973.
4. Francis RB Jr, Feinstein DI. Clinical significance of accelerated fibrinolysis in liver disease. Haemostasis 1984;14:460-465.
5. Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. HEPATOLOGY 2003;38:230-237.
6. Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001;121:131-139.
7. Ben-Ari Z, Osman E, Hutton RA, Burroughs AK. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenrerol 1999;94:2977-2982.
8. Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. Thromb Haemost 2004;91:267-275.
9. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. HEPATOLOGY 1985;5:419-424.
10. Boks AL, Brommer EJ, Schalm SW, Van Vliet HH. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. HEPATOLOGY 1986;6:79-86.
11. Morrissey JH. Tissue factor: a key molecule in hemostatic and non hemostatic systems. Int J Hematol 2004;79:103-108.
12. Mann KG. Thrombin formation. Chest 2003;124(Suppl 3):4S-10S.
13. Dahlback B. Progress in the understanding of the protein C anticoagulant pathway. Int J Hematol 2004;79:109-116.
14. Lane DA, Caso R. Antithrombin: structure, genomic organization, function and inherited deficiency. Baillieres Clin Haematol 1989;2:961-998.
15. Huntington JA. Mechanisms of glycosaminoglycan activation of the serpins in hemostasis. J Thromb Haemost 2003;1:1535-1549.
16. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001;86:959-972.
17. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003;1:1504-1514.
18. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989;264:4743-4746.
19. Hemker HC, Beguin S. Phenotyping the clotting system. Thromb Haemost 2000;84;747-751.
20. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transaction of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
21. Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993;70:617-624.
22. Chantarangkul V, Clerici M, Bressi A, Giesen PL, Tripodi A. Thrombin generation assessed as endogenous thrombin potential (ETP) in patients with hypo- or hyper-coagulability. Effects of phospholipids, tissue factor and residual platelets on the measurement performed in platelet-poor and platelet-rich plasma. Haematologica 2003;88:547-554.
23. Tripodi A, Arbini A, Chantarangkul V, Mannucci PM. Recombinant tissue factor as substitute for conventional thromboplastin in the prothrombin time test. Thromb Haemost 1992;67:42-45.
24. Bertina RM, van der Marel-van Nieuwkoop W, Loeliger EA. Spectrophotometric assays of prothrombin in plasma of patients using oral anticoagulants. Thromb Haemost 1979;42:1296-1305.
25. Mannucci PM, Tripodi A. Factor VIII clotting activity. In: Jespersen J, Bertina RM, Haverkate F, eds. Laboratory Techniques in Thrombosis. A Manual. Dordrecht: Kluwer Academic Publishers, 1999:107-113.
26. Cvrin G, Gallistl S, Leschnik B, Muntean W. Low tissue factor pathway inhibitor (TFPI) together with low antithrombin allows sufficient thrombin generation in neonates. J Thromb Haemost 2003;1:263-268.
27. O'Donnell J, Mumford AD, Manning RA, Laffan MA. Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. Br J Haematol 2001;115:687-691.
28. Oksuzoglu G, Simsek H, Haznedaroglu IC, Kirazli S. Tissue factor pathway inhibitor concentrations in cirrhotic patients with and without portal vein thrombosis. Am J Gastroenterol 1997;92:303-306.
29. Bosch J, Thabut D, Bendtsen F, D'Amico G, Albillos A, Gonzalez Abraldes J, et al.; European Study Group on rFVIIa in UGI Haemorrhage. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology. 2004; 127:1123-1130.
30. Uhlmann EJ, Eby CS. Recombinant activated factor VII for non-hemophiliac bleeding patients. Curr Opin Hematol 2004;11:198-204.